RBC Capital Reiterates Outperform on NewAmsterdam Pharma, Maintains $31 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Leonid Timashev has reiterated an Outperform rating on NewAmsterdam Pharma (NASDAQ:NAMS) and maintained a $31 price target.
June 07, 2024 | 2:39 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital has reiterated an Outperform rating on NewAmsterdam Pharma and maintained a $31 price target, indicating continued confidence in the company's performance.
The reiteration of an Outperform rating and the maintenance of a $31 price target by RBC Capital suggests strong confidence in NewAmsterdam Pharma's future performance. This is likely to positively impact the stock price in the short term as investors may view this as a bullish signal.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100